IL1B and type 2 diabetes mellitus: However, a recent clinical study of Canakinumab, a humanized monoclonal antibody against IL-1β, revealed that blocking IL-1β does not improve glycemic control in T2DM patients, despite leading to a reduction in inflammation [73].